Entrada Therapeutics, Inc. (TRDA) Free Cash Flow by Year
Entrada Therapeutics, Inc. recorded an outflow of $129.6M in free cash flow in fiscal year 2025. This represents a decrease of 189.7% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to an outflow of $135.1M in free cash flow. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Entrada Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
TRDA Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
TRDA Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Entrada Therapeutics, Inc. financials
Frequently Asked Questions
What was Entrada Therapeutics, Inc.'s free cash flow in fiscal year 2025?
Entrada Therapeutics, Inc. recorded an outflow of $129.6M in free cash flow in fiscal year 2025.
How fast is Entrada Therapeutics, Inc.'s free cash flow growing?
Entrada Therapeutics, Inc. (TRDA) free cash flow fell by 189.7% year over year, from -$44.7M to -$129.6M in fiscal year 2025.
What is Entrada Therapeutics, Inc.'s free cash flow over the last twelve months?
Entrada Therapeutics, Inc. (TRDA) reported an outflow of $135.1M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Entrada Therapeutics, Inc.'s free cash flow changed over the years?
Across the 6 fiscal years this page covers, Entrada Therapeutics, Inc. (TRDA) free cash flow went from -$27.9M in fiscal year 2020 to -$129.6M in fiscal year 2025.
What was Entrada Therapeutics, Inc.'s free cash flow in the most recent quarter?
Entrada Therapeutics, Inc. (TRDA) reported -$32.5M in free cash flow in Q2 2026. This represents a decrease of 9.1% from the same quarter a year earlier.
What does free cash flow mean on a financial statement?
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Entrada Therapeutics, Inc. (TRDA) reported on that line in every period on record.